NanoTess is a healthcare startup that specializes in the development and commercialization of nanomaterial platform technologies. Their primary product, NanoSALV Catalytic Advanced Wound Care Treatment Matrix, is a Health Canada approved medical device designed to optimize wound healing, reduce inflammation, and provide effective antimicrobial protection. The company operates in the healthcare market, specifically targeting healthcare professionals and patients suffering from chronic wounds such as diabetic foot ulcers.

The business model of NanoTess is based on the development, validation, and commercialization of their proprietary technology, NanoKARE™. This novel nano-structured material is designed to reduce the thresholds needed for optimal healing outcomes, modulate healthy inflammation, and provide safe and effective broad-spectrum antimicrobial and biofilm protection. By offering this technology in an easy-to-apply and manage matrix gel, NanoTess is able to bring value to all stakeholders, including patients, healthcare professionals, and investors.

The company makes money by selling their NanoSALV Catalytic Advanced Wound Care Treatment Matrix to healthcare professionals. With the cost of caring for chronic wounds in the US exceeding $50 billion annually, there is a significant market for their product.

In conclusion, NanoTess is a promising startup that leverages nanotechnology to address some of the world's toughest health-related challenges, particularly in the area of chronic wound care.

Keywords: NanoTess, Healthcare, Nanotechnology, Chronic Wound Care, NanoSALV, NanoKARE™, Medical Device, Inflammation Reduction, Antimicrobial Protection, Diabetic Foot Ulcers.